Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 18/20 | 0.41 |
| ▸ | DHFR | P00374 | 4/20 | 0.41 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.41 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.41 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.41 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.41 |
| ▸ | GART | P22102 | 1/20 | 0.41 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658541 | 0.85 | TYMS (0.49) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL28690321 | 0.74 | TYMS (0.51) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL20064089 | 0.71 | NOS1 (0.37) | TYMS | |
| SCHEMBL25476851 | 0.69 | TYMS (0.64) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL19901167 | 0.68 | KMT2A (0.54) | — | |
| SCHEMBL23394652 | 0.67 | TYMS (0.63) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL24845716 | 0.67 | PNP (0.57) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL8855177 | 0.67 | TYMS (0.61) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL22084411 | 0.67 | TYMS (0.62) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL13659935 | 0.66 | TYMS (0.63) | TYMSDHFRFOLR1SLC19A1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190099493-A1 | Targeting Lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099493-A1 | Targeting Lipids | APOB, LY96, ABHD10 | TYMS 2545/4885DHFR 1469/4885FOLR1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.